IL81370A - Pharmaceutical and diagnostic compositions comprising a plurality of human monoclonal antibodies for the treatment of bacterial diseases,methods for the preparation of the compositions and antibodies and kits containing said compositions - Google Patents

Pharmaceutical and diagnostic compositions comprising a plurality of human monoclonal antibodies for the treatment of bacterial diseases,methods for the preparation of the compositions and antibodies and kits containing said compositions

Info

Publication number
IL81370A
IL81370A IL81370A IL8137087A IL81370A IL 81370 A IL81370 A IL 81370A IL 81370 A IL81370 A IL 81370A IL 8137087 A IL8137087 A IL 8137087A IL 81370 A IL81370 A IL 81370A
Authority
IL
Israel
Prior art keywords
compositions
antibodies
pharmaceutical
preparation
treatment
Prior art date
Application number
IL81370A
Other languages
English (en)
Other versions
IL81370A0 (en
Original Assignee
Genetic Systems Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetic Systems Corp filed Critical Genetic Systems Corp
Publication of IL81370A0 publication Critical patent/IL81370A0/xx
Publication of IL81370A publication Critical patent/IL81370A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL81370A 1986-02-07 1987-01-23 Pharmaceutical and diagnostic compositions comprising a plurality of human monoclonal antibodies for the treatment of bacterial diseases,methods for the preparation of the compositions and antibodies and kits containing said compositions IL81370A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82800586A 1986-02-07 1986-02-07
US94449586A 1986-12-19 1986-12-19

Publications (2)

Publication Number Publication Date
IL81370A0 IL81370A0 (en) 1987-08-31
IL81370A true IL81370A (en) 1991-06-30

Family

ID=27125154

Family Applications (1)

Application Number Title Priority Date Filing Date
IL81370A IL81370A (en) 1986-02-07 1987-01-23 Pharmaceutical and diagnostic compositions comprising a plurality of human monoclonal antibodies for the treatment of bacterial diseases,methods for the preparation of the compositions and antibodies and kits containing said compositions

Country Status (28)

Country Link
US (2) US5717071A (xx)
JP (1) JP2645343B2 (xx)
KR (1) KR870007697A (xx)
CN (1) CN87102167A (xx)
AT (1) AT398781B (xx)
BE (1) BE1000967A5 (xx)
CA (1) CA1339013C (xx)
CH (1) CH672072A5 (xx)
DE (1) DE3703711A1 (xx)
DK (1) DK63187A (xx)
ES (1) ES2009140A6 (xx)
FI (1) FI94489C (xx)
FR (1) FR2595946B1 (xx)
GB (1) GB2186592B (xx)
GR (1) GR870194B (xx)
HK (1) HK21795A (xx)
HU (1) HU203583B (xx)
IE (1) IE59627B1 (xx)
IL (1) IL81370A (xx)
IT (1) IT1207589B (xx)
LU (1) LU86761A1 (xx)
MX (1) MX9203629A (xx)
NL (1) NL8700286A (xx)
NO (1) NO176924C (xx)
NZ (2) NZ219187A (xx)
OA (1) OA08477A (xx)
PT (1) PT84258B (xx)
SE (1) SE468747B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256713A3 (en) * 1986-08-06 1989-02-15 Merck & Co. Inc. Therapeutic human antipseudomonas aeruginosa antibodies
CA1341375C (en) * 1988-10-12 2002-07-09 Baxter International Inc. Compositions and methods for the treatment and prevention of gram-negative bacterial infections
DE3925161A1 (de) * 1989-03-15 1990-09-27 Boehringer Mannheim Gmbh Monoklonale, gegen eca gerichtete antikoerper und ihre verwendung
JPH0329196A (ja) * 1989-05-09 1991-02-07 Advanced Micro Devicds Inc センス増幅器
US6315999B1 (en) 1989-08-10 2001-11-13 Solvay, S.A. Pharmaceutical product for the treatment of sepsis
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
US20080139789A1 (en) * 1990-10-22 2008-06-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection
EP0635132B2 (en) * 1992-03-19 2008-05-14 Henry M. Jackson Foundation For The Advancement Of Military Medicine Broadly reactive opsonic antibodies that react with common staphylococcal antigens
CA2153661A1 (en) * 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
US5510264A (en) * 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
ATE474849T1 (de) * 1998-04-14 2010-08-15 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
CA2694466A1 (en) * 2007-07-23 2009-01-29 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
US8444983B2 (en) * 2009-03-23 2013-05-21 Quark Pharmaceuticals, Inc. Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases
BR112013013702A2 (pt) 2010-12-03 2016-09-13 Sanofi Pasteur Ltd composição para imunização contra streptococcus pneumoniae
US11168131B2 (en) 2015-11-10 2021-11-09 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
KR102697723B1 (ko) 2017-01-18 2024-08-21 비스테라, 인크. 항체 분자-약물 접합체 및 이의 용도
WO2021203024A1 (en) 2020-04-03 2021-10-07 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464465A (en) * 1982-04-05 1984-08-07 Genetic Systems Corporation Cell-driven viral transfer in eukaryotes
CA1262238C (en) * 1982-09-30 1989-10-10 HUMAN MONOCLONAL ANTIBODIES AGAINST BACTERIAL TOXINS
US4587121A (en) * 1983-06-14 1986-05-06 Miles Laboratories, Inc. High titer Pseudomonas immune serum globulin
US5179018A (en) * 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
US4834975A (en) * 1984-05-25 1989-05-30 Genetics Corporation Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production
DE3426903A1 (de) * 1984-07-20 1986-01-23 Biotest Pharma GmbH, 6000 Frankfurt Eine immunglobulinpraeparation in kombination mit einer anderen pharmakologisch wirksamen praeparation zur verwendung bei der behandlung von krankheiten
US4675287A (en) * 1984-07-26 1987-06-23 Scripps Clinic And Research Foundation Monoclonal antibody directed to human ganglioside GD2
US4677070A (en) * 1985-04-26 1987-06-30 Cetus Corporation Pseudomonas aeruginosa exotoxin A antibodies, their preparation and use
US4772464A (en) * 1985-08-01 1988-09-20 Miles Laboratories, Inc. Protective antibodies to serotypic determinants of flagellar antigens
US4777136A (en) * 1985-09-27 1988-10-11 The Regents Of The University Of California Monoclonal antibody reactive with Pseudomonas Aeruginosa
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
NZ218499A (en) * 1985-12-10 1990-04-26 Genetic Systems Corp Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods
US4970070A (en) * 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus

Also Published As

Publication number Publication date
ES2009140A6 (es) 1989-09-01
IE870320L (en) 1987-08-07
NZ219187A (en) 1990-12-21
NO870476D0 (no) 1987-02-06
CN87102167A (zh) 1988-02-03
FI94489C (fi) 1995-09-25
HUT46062A (en) 1988-09-28
PT84258A (en) 1987-03-01
NO176924C (no) 1995-06-21
FI94489B (fi) 1995-06-15
IL81370A0 (en) 1987-08-31
HK21795A (en) 1995-02-24
FR2595946A1 (fr) 1987-09-25
DE3703711A1 (de) 1987-09-24
US5837541A (en) 1998-11-17
JPS62270535A (ja) 1987-11-24
CA1339013C (en) 1997-03-25
CH672072A5 (xx) 1989-10-31
DK63187D0 (da) 1987-02-06
LU86761A1 (fr) 1987-09-15
DK63187A (da) 1987-08-08
NZ233920A (en) 1990-12-21
DE3703711C2 (xx) 1993-06-24
IE59627B1 (en) 1994-03-09
IT1207589B (it) 1989-05-25
SE8700467D0 (sv) 1987-02-06
NL8700286A (nl) 1987-09-01
GB2186592B (en) 1990-08-01
KR870007697A (ko) 1987-09-21
NO870476L (no) 1987-08-10
HU203583B (en) 1991-08-28
GB8702689D0 (en) 1987-03-11
FI870502A (fi) 1987-08-08
JP2645343B2 (ja) 1997-08-25
GB2186592A (en) 1987-08-19
FR2595946B1 (fr) 1991-10-04
OA08477A (fr) 1988-07-29
ATA26287A (de) 1994-06-15
IT8719292A0 (it) 1987-02-06
BE1000967A5 (fr) 1989-05-30
SE8700467L (sv) 1987-08-08
GR870194B (en) 1987-06-10
MX9203629A (es) 1992-07-01
AT398781B (de) 1995-01-25
SE468747B (sv) 1993-03-15
FI870502A0 (fi) 1987-02-06
PT84258B (pt) 1989-09-14
NO176924B (no) 1995-03-13
US5717071A (en) 1998-02-10

Similar Documents

Publication Publication Date Title
IL81370A (en) Pharmaceutical and diagnostic compositions comprising a plurality of human monoclonal antibodies for the treatment of bacterial diseases,methods for the preparation of the compositions and antibodies and kits containing said compositions
AU4297685A (en) Compositions for the allevation, treatment and diagnosis of arthritic disease and related conditions
DE3269625D1 (en) Benzazepin-2-ones, process for their preparation, pharmaceutical preparations containing these compounds and the compounds for therapeutical use
AU590403B2 (en) Pharmaceutical composition for the treatment of periodontal diseases
LV10654B (en) Method for preparation of diagnostic composition and the use thereof
EP0240975A3 (en) Human gamma interferon-specific receptor protein, antibody against said protein, methods for obtaining said protein and said antibody and compositions containing said protein and antibody
GB8806339D0 (en) Monoclonal antibodies
EP0334962A4 (en) Method for diagnosis of cancer diseases
EP0506893A4 (en) Diagnosis and treatment of diseases
AU6974687A (en) Treatment of immune diseases using diphenylhydantoin
KR950700726A (ko) 치료 또는 진단용 조성물, 그 제조방법 및 용도(composition for therapeutic or diagnostic use, process for its preparation and its use)
AU2792789A (en) Method and means for selection of anti-idiotype antibodies and their use for the diagnosis, monitoring, treatment and/or prevention of cancer, autoimmune or infectious disease
IL83194A0 (en) Beta-lactam compound,method for preparing the same,medicinal composition containing the same for infectious bacterial disease therapy and intermediates for synthesis of the same
ZA904565B (en) Peptides and antibodies derived therefrom for the diagnosis of therapy for and vaccination against htlv-1 infection
PT74927B (en) Method for the preparation of pharmaceutical compositions for the treatment of skin
GR860486B (en) Novel cephalosporines method for their preparation and their use as medicine
PT84755A (en) Process for the preparation of a pharmaceutical composition for the treatment of skin diseases
AU591017B2 (en) Human monoclonal antibody and drug for prophylaxis and treatment of infectious diseases comprising same as effective ingredient
EP0270682A4 (en) NEW COMPLEXES, PROCESS FOR THEIR PREPARATION, AND THEIR MEDICINAL USE.
DE3790139D2 (en) Antiparatypical antibodies, their use for detecting and treating auto-immune diseases
IL86960A0 (en) Preparation of human monoclonal antibodies
EP0248361A3 (en) Pharmaceutical preparation for the treatment of bacterial infections
AR244211A1 (es) Procedimiento para la elaboracion de acidos 3-amino-(1)benzazepin-2-ona-1-alcanoicos y sus sales y esteroisomeros.
AU5675790A (en) Human monoclonal antibodies to sero-specific determinants of gram-negative bacteria
AU8864791A (en) Antibodies and methods for diagnosis and treatment of diabetes

Legal Events

Date Code Title Description
RH Patent void